AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21997545
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aspirin with colonoscopy and sigmoidoscopy
Trial: 15351765
Drug: Cognitive enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive enhancement therapy
Trial: 15351765
Drug: Enriched supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched supportive therapy
Trial: 16234012
Drug: 50 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mug IFN-gamma intramuscularly daily for 3 months and on alternate days for the subsequent 6 months
Trial: 12399271
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g almonds/d for 4 wk
Trial: 10196648
Drug: Oral pseudoephedrine
RxNorm normalized name: pseudoephedrine Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pseudoephedrine (60 mg capsule)
Trial: 2177062
Drug: Lisinopril (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10, 20, and 40 mg once-daily)
Trial: 2177062
Drug: Captopril (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25, 50, and 100 mg twice-daily)
Trial: 389483
Drug: Diphenylhydantoin (DPH)
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenylhydantoin (DPH) therapy for 2 years
Trial: 389483
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no DPH therapy)
Trial: 30238239
Drug: Early stage
RxNorm normalized name: SALICYLIC ACID 0.14 mg TOPICAL PATCH [Peace Out Early Stage Acne Dot]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early stage periarticular injection (just prior to arthrotomy)
Trial: 30238239
Drug: Late stage
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late stage periarticular injection (after implanting the prosthesis)
Trial: 21459271
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin for median duration of 28 months
Trial: 19632099
Drug: Atorvastatin (n=22)
RxNorm normalized name: 22:6(n-3)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (n=22)
Trial: 17565514
Drug: 1.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% lidocaine (Group L)
Trial: 15581045
Drug: Paclitaxel-gemcitabine-trastuzumab (TGH)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-gemcitabine-trastuzumab (TGH) regimen: paclitaxel 80 mg/m2/week, gemcitabine 1000 mg/m2 every 2 weeks, trastuzumab 4 mg/kg loading dose then 2 mg/kg/week for 12 weeks
Trial: 3221746
Drug: Droxicam 20
RxNorm normalized name: droxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droxicam 20 mg/day for 20 days
Trial: 3221746
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg/day for 20 days
Trial: 29941861
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine spray (TL group)
Trial: 29941861
Drug: 1 mg/kg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/h lidocaine infusion (GL group)
Trial: 11564123
Drug: Levetiracetam 3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam 3,000 mg/day
Trial: 15290665
Drug: Gabexate mesylate
RxNorm normalized name: mesylate
DrugBank: Gabexate (DB12831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesylate (500 mg; n = 381)
Trial: 9313755
Drug: Factor analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor analysis of fasting and 2-h postchallenge insulin levels, fasting triglyceride and HDL cholesterol levels, BMI, and waist-to-hip ratio.
Trial: 9313755
Drug: Factor analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor analysis of fasting and 2-h levels of glucose and insulin.
Trial: 3316152
Drug: Norfloxacin 200
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin 200 mg bid
Trial: 20976768
Drug: Dalfampridine (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine (10mg twice daily)
Trial: 16841342
Drug: Clinician‐Administered PTSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician‐Administered PTSD Scale for DSM‐IV (CAPS)
Trial: 10332907
Drug: Women's Safety
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women's Safety in Recovery group (N=48), met three times weekly for one hour
Trial: 10332907
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (N=38)
Trial: 30547267
Drug: pH-neutral solutions
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-neutral solutions
Trial: 28384480
Drug: L-Tyrosine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Tyrosine administration
Trial: 28384480
Drug: Bilateral tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral tDCS over DLPFC with L-Tyrosine
Trial: 25738670
Drug: VR-CAP (R-CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VR-CAP (R-CHOP regimen with bortezomib at a dose of 1.3 mg/m² on days 1, 4, 8, and 11)
Trial: 23921656
Drug: Licorice gargle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licorice gargle (Extractum Liquiritiae Fluidum, 0.5 g in 30 mL water)
Trial: 23921656
Drug: Sugar-water gargle
RxNorm normalized name: SUGAR/WATER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-water gargle (Sirupus Simplex, 5 g in 30 mL water)
Trial: 20673585
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G‐CSF) as an adjunct to de novo AML remission induction therapy
Trial: 15148493
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G‐CSF)
Trial: 15086539
Drug: Misoprostol (0.4‐0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (0.4‐0.8 mg per day) for 6 weeks
Trial: 11473954
Drug: Oral HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HRT (2 mg oestradiol on days 1‐‐12, 2 mg oestradiol plus 1 mg norethisterone acetate (NETA) on days 13‐‐22, and 1 mg oestradiol on days 23‐‐28, n = 19)
Trial: 11473954
Drug: Transdermal HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal HRT (50 microg/day of oestradiol on days 1‐‐13, and 50 microg oestradiol plus 250 microg/day NETA on days 14‐‐28, n = 19)
Trial: 8052367
Drug: Intermittent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent administration of 0.75 microgram calcitriol twice weekly (total weekly dose of 5.25 micrograms)
Trial: 8052367
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration of 0.75 microgram calcitriol daily (total weekly dose of 5.25 micrograms)
Trial: 20688442
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg 17β-oestradiol/2.5 mg dydrogesterone (E 0.5 mg/D 2.5 mg)
Trial: 20688442
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg 17β-oestradiol/5 mg dydrogesterone (E 1mg/D 5 mg)
Trial: 20688442
Drug: E 0.5
RxNorm normalized name: iodine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E 0.5 mg/D 2.5 mg
Trial: 15196155
Drug: Intramuscular penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular penicillin (2 MU x 2 times daily)
Trial: 15196155
Drug: Intravenous benzyl
RxNorm normalized name: Benzyl Alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous benzyl penicillin (4 MU x 6 times daily)
Trial: 15196155
Drug: Intravenous benzyl
RxNorm normalized name: Benzyl Alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous benzyl penicillin
Trial: 15196155
Drug: Intramuscular penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular penicillin
Trial: 9405029
Drug: HRT (sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate)
Trial: 9405029
Drug: Placebo (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (calcium lactate 500 mg/day)
Trial: 26177352
Drug: Nonoxynol-9 (N9)
RxNorm normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoxynol-9 (N9) gel
Trial: 26177352
Drug: Universal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal placebo gel (UPG)
Trial: 23022105
Drug: Vacuum-cast Co-Cr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-cast Co-Cr (CC)
Trial: 22229185
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg/d
Trial: 17467059
Drug: Nefazodone in
RxNorm normalized name: Product containing nefazodone in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone in combination with interpersonal psychotherapy (IPT)
Trial: 17467059
Drug: IPT in
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPT in combination with placebo
Trial: 11719944
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tea extracts with sodium lauryl sulfate (1.2% w/v)
Trial: 9207726
Drug: Budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nasal spray, 50 micrograms to each nostril, bid for 3 weeks
Trial: 9207726
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray, bid for 3 weeks
Trial: 8432773
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human GH (0.25-0.5 U/kg.week, administered sc daily at bedtime)
Trial: 3435129
Drug: Intravenous cefodizime
RxNorm normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefodizime (1 g)
Trial: 3435129
Drug: Intramuscular cefodizime
RxNorm normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular cefodizime (1 g)
Trial: 26890440
Drug: Postpartum antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postpartum antibiotic prophylaxis
Trial: 26890440
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment following delivery
Trial: 26890440
Drug: Post-CD antibiotics
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-CD antibiotics (meta-analysis)
Trial: 26890440
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (meta-analysis)
Trial: 25124305
Drug: Δ(9)‐THC (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δ(9)‐THC (30 mg)
Trial: 25124305
Drug: Diazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5 mg) + Δ(9)‐THC (5, 15, 30 mg)
Trial: 25124305
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg) + Δ(9)‐THC (5, 15, 30 mg)
Trial: 23823799
Drug: Agomelatine (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine (25-50 mg/d)
Trial: 12192263
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field therapy
Trial: 10642057
Drug: L-carnitine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (100 mg/kg per 24 h per os)
Trial: 493093
Drug: acebutolol in
RxNorm normalized name: acebutolol Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebutolol in combination with a diuretic
Trial: 24569618
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg daily for 12 weeks
Trial: 25858497
Drug: Masitinib plus
RxNorm normalized name: masitinib
DrugBank: Masitinib (DB11526)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masitinib plus gemcitabine (masitinib 9 mg/kg/day, gemcitabine 1000 mg/m²)
Trial: 25858497
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus gemcitabine (placebo, gemcitabine 1000 mg/m²)
Trial: 20727239
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium and vitamin D supplementation for low bone density (LBD) women.
Trial: 19386548
Drug: Standard-dose PCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose PCI (25 Gy in 10 daily fractions of 2.5 Gy)
Trial: 19386548
Drug: Higher-dose PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose PCI (36 Gy delivered using either conventional or accelerated hyperfractionated radiotherapy)
Trial: 19386548
Drug: Standard-dose PCI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose PCI (25 Gy)
Trial: 19386548
Drug: Higher-dose PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose PCI (36 Gy)
Trial: 11294370
Drug: GW420867X 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW420867X 10 mg
Trial: 11294370
Drug: GW420867X 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW420867X 50 mg
Trial: 11294370
Drug: GW420867X 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW420867X 100 mg
Trial: 11294370
Drug: GW420867X 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW420867X 200 mg
Trial: 795190
Drug: 0.2% flumethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% flumethasone ointment
Trial: 22251106
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at an effect-site concentration of 4.0 ng.ml(‐1) with maximal flow rate limited to 100 ml.h(‐1) (group R(100))
Trial: 22251106
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at an effect-site concentration of 4.0 ng.ml(‐1) with maximal flow rate limited to 200 ml.h(‐1) (group R(200))
Trial: 22251106
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at an effect-site concentration of 4.0 ng.ml(‐1) with maximal flow rate limited to 1200 ml.h(‐1) (group R(1200))
Trial: 20572767
Drug: ω‐3 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 group (SRP + dietary supplementation of fish oil 900 mg EPA + DHA + 81 mg aspirin daily)
Trial: 16082528
Drug: Losartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan treatment in patients with LVH
Trial: 1826569
Drug: Monophasic oral
RxNorm normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel (Marvelon, group A)
Trial: 1826569
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive containing 30-40 micrograms ethinyloestradiol and 50-125 micrograms levonorgestrel (Triphasil, group B)
Trial: 6149538
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate 100 mg/day in two divided doses
Trial: 30496547
Drug: Dance Movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dance Movement Therapy (DMT)
Trial: 27858846
Drug: L +
RxNorm normalized name: Citracal + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L + D group (fractional CO2 laser + luliconazole 1% cream)
Trial: 27858846
Drug: L group
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L group (fractional CO2 laser alone)
Trial: 20847065
Drug: Late remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late remote ischaemic preconditioning (L‐RIPC) consisting of three five-minute cycles of upper limb ischaemia and three five-minute pauses using blood pressure cuff inflation 18 hours prior to the operation.
Trial: 20847065
Drug: Tramadol 200
RxNorm normalized name: TRAMADOL 200MG (RYZOLT) SA TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 200 mg retard administered at 19:00 hours the day before the operation and at 06:00 hours on the day of the operation.
Trial: 20847065
Drug: Late remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late remote ischaemic preconditioning (L‐RIPC).
Trial: 12843894
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate 0.2% drops twice the day before and twice on the day of the operation
Trial: 1957331
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) administration of 0.6 mg digoxin
Trial: 1957331
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) administration of 1.2 mg digoxin
Trial: 1957331
Drug: Oral (p.o.)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (p.o.) administration of 0.6 mg digoxin
Trial: 1957331
Drug: Oral (p.o.)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (p.o.) administration of 1.2 mg digoxin
Trial: 6313028
Drug: Theophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (6 mg/kg) while standing
Trial: 6313028
Drug: Theophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (6 mg/kg) while supine
Trial: 6313028
Drug: Theophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (6 mg/kg) while standing vs supine
Trial: 29359722
Drug: Standard infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard infusion therapy (Control)
Trial: 24965957
Drug: Pilates method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates method with NSAID treatment
Trial: 24965957
Drug: NSAID treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID treatment without Pilates
Trial: 23818768
Drug: Daily antioxidant
RxNorm normalized name: Ascorbic Acid/Selenium/Vitamin A/Vitamin E Oral Capsule, Liquid Filled [DAILY ANTIOXIDANT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily antioxidant and essential polyunsaturated fatty acid supplement (two pills) for 3 months (+S)
Trial: 11720628
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical and surgical therapy
Trial: 7048915
Drug: Acyclovir applied
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir applied topically four times daily for 10 days
Trial: 7048915
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied topically four times daily for 10 days
Trial: 24184576
Drug: Intranasally administered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally administered oxytocin (16 IU)
Trial: 22044433
Drug: Flupirtine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine (400 mg/day, titrated to 600 mg/day)
Trial: 22044433
Drug: Tolterodine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine (4 mg/day)
Trial: 18199844
Drug: CAPD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPD with a target creatinine clearance > or =60 L/wk/1.73 m(2)
Trial: 8627061
Drug: Interferon alfa‐n3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐n3 (IFN‐alpha n3) 1 mega‐IU (MIU)/dose
Trial: 8627061
Drug: Interferon alfa‐n3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐n3 (IFN‐alpha n3) 5 MIU/dose
Trial: 8627061
Drug: Interferon alfa‐n3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐n3 (IFN‐alpha n3) maximum tolerated dose
Trial: 1471382
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg pantoprazole o.m.
Trial: 1471382
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pantoprazole o.m.
Trial: 1471382
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg pantoprazole o.m.
Trial: 20108156
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.5% bupivacaine (50 mg)
Trial: 20108156
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of sterile water
Trial: 15641037
Drug: Cisplatin 70
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 70 mg/m2 on Day 1, etoposide 50 mg/m2 on Days 1-3, and gemcitabine 1000 mg/m2 on Days 1 and 8 (PEG)